![Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies | SpringerLink Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00280-022-04456-w/MediaObjects/280_2022_4456_Fig1_HTML.png)
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies | SpringerLink
![Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/e9258ca8-ad6d-4d07-a3e2-5428e63fc2a4/gr1.jpg)
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology
![Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804917307359-gr1.jpg)
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect
![Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology - Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology -](https://bpspubs.onlinelibrary.wiley.com/cms/asset/ca2685cb-d6e2-4a06-b515-6e38b2a2e629/bcp13982-fig-0003-m.jpg)
Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology -
![A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086415305153-gr1.jpg)
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect
![Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-019-00909-6/MediaObjects/12325_2019_909_Fig1_HTML.png)
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink
![Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism | Cell Death Discovery Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism | Cell Death Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41420-021-00511-2/MediaObjects/41420_2021_511_Fig1_HTML.png)
Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism | Cell Death Discovery
![Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology - Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology -](https://bpspubs.onlinelibrary.wiley.com/cms/asset/2639506e-55c5-4b54-b453-ec3762a5deff/bcp13982-fig-0001-m.jpg)